Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Degraded neutrophil extracellular traps promote the growth of Actinobacillus pleuropneumoniae.

de Buhr N, Bonilla MC, Pfeiffer J, Akhdar S, Schwennen C, Kahl BC, Waldmann KH, Valentin-Weigand P, Hennig-Pauka I, von Köckritz-Blickwede M.

Cell Death Dis. 2019 Sep 10;10(9):657. doi: 10.1038/s41419-019-1895-4.

2.

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.

Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Spielewoy N, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0559-9. [Epub ahead of print]

PMID:
31462735
3.

A retrospective analysis of the pathogens in the airways of patients with primary ciliary dyskinesia.

Roden L, Görlich D, Omran H, Peters G, Große-Onnebrink J, Kahl BC.

Respir Med. 2019 Sep;156:69-77. doi: 10.1016/j.rmed.2019.08.009. Epub 2019 Aug 15.

PMID:
31437650
4.

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW.

Blood. 2019 Jul 22. pii: blood.2019000719. doi: 10.1182/blood.2019000719. [Epub ahead of print]

PMID:
31331918
5.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Acta Haematol. 2019 Jul 17:1-11. doi: 10.1159/000500666. [Epub ahead of print]

PMID:
31315113
6.

Interference with Pseudomonas aeruginosa quorum sensing and virulence by the mycobacterial PQS dioxygenase AqdC in combination with the N-acylhomoserine lactone lactonase QsdA.

Birmes FS, Säring R, Hauke MC, Ritzmann NH, Drees SL, Daniel J, Treffon J, Liebau E, Kahl BC, Fetzner S.

Infect Immun. 2019 Jul 15. pii: IAI.00278-19. doi: 10.1128/IAI.00278-19. [Epub ahead of print]

PMID:
31308081
7.

Phenotypic and Genotypic Characterization of Escherichia coli Causing Urinary Tract Infections in Kidney-Transplanted Patients.

Abo Basha J, Kiel M, Görlich D, Schütte-Nütgen K, Witten A, Pavenstädt H, Kahl BC, Dobrindt U, Reuter S.

J Clin Med. 2019 Jul 7;8(7). pii: E988. doi: 10.3390/jcm8070988.

8.

Course of platelet miRNAs after cessation of P2Y12 antagonists.

Jäger B, Stojkovic S, Haller PM, Piackova E, Kahl BS, Andric T, Vargas KG, Wojta J, Huber K.

Eur J Clin Invest. 2019 Aug;49(8):e13149. doi: 10.1111/eci.13149. Epub 2019 Jun 23.

PMID:
31172515
9.

The prevalence of Staphylococcus aureus with mucoid phenotype in the airways of patients with cystic fibrosis-A prospective study.

Lennartz FE, Schwartbeck B, Dübbers A, Große-Onnebrink J, Kessler C, Küster P, Schültingkemper H, Peters G, Kahl BC.

Int J Med Microbiol. 2019 Jul;309(5):283-287. doi: 10.1016/j.ijmm.2019.05.002. Epub 2019 May 11.

PMID:
31122879
10.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP.

J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.

PMID:
30939090
11.

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM.

J Immunother Cancer. 2019 Mar 12;7(1):70. doi: 10.1186/s40425-019-0538-8.

12.

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM.

J Clin Oncol. 2019 Apr 20;37(12):984-991. doi: 10.1200/JCO.18.00605. Epub 2019 Feb 27.

PMID:
30811293
13.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.

PMID:
30723079
14.

Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy.

Jäger B, Piackova E, Haller PM, Andric T, Kahl B, Christ G, Geppert A, Wojta J, Huber K.

Arch Med Sci. 2019 Jan;15(1):65-71. doi: 10.5114/aoms.2018.81035. Epub 2018 Dec 30.

15.

Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.

Kahl BS, Dreyling M, Gordon LI, Martin P, Quintanilla-Martinez L, Sotomayor EM.

Leuk Lymphoma. 2019 Aug;60(8):1853-1865. doi: 10.1080/10428194.2019.1571205. Epub 2019 Jan 30.

PMID:
30696305
16.

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR; COMPLETE Investigators.

Cancer. 2019 May 1;125(9):1507-1517. doi: 10.1002/cncr.31861. Epub 2019 Jan 29.

PMID:
30694529
17.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jan;17(1):12-20. doi: 10.6004/jnccn.2019.0002.

PMID:
30659125
18.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ.

Leuk Lymphoma. 2019 Aug;60(8):1934-1941. doi: 10.1080/10428194.2018.1563691. Epub 2019 Jan 10.

PMID:
30628511
19.

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.

Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS.

Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.

PMID:
30575016
20.

Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?

Landsburg DJ, Kahl BS.

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):65-67. doi: 10.1016/j.clml.2018.11.017. Epub 2018 Nov 24. No abstract available.

PMID:
30555036
21.

Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma.

Kahl BS.

Clin Adv Hematol Oncol. 2018 Nov;16(11):732-734. Review. No abstract available.

PMID:
30543588
22.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868
23.

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hernández-Rivas JÁ, Qi K, Deshpande S, Parisi L, Wang M.

Haematologica. 2019 May;104(5):e211-e214. doi: 10.3324/haematol.2018.205229. Epub 2018 Nov 15. No abstract available.

24.

In vivo competition and horizontal gene transfer among distinct Staphylococcus aureus lineages as major drivers for adaptational changes during long-term persistence in humans.

Langhanki L, Berger P, Treffon J, Catania F, Kahl BC, Mellmann A.

BMC Microbiol. 2018 Oct 22;18(1):152. doi: 10.1186/s12866-018-1308-3.

25.

Evolving treatment strategies in mantle cell lymphoma.

Edwin NC, Kahl B.

Best Pract Res Clin Haematol. 2018 Sep;31(3):270-278. doi: 10.1016/j.beha.2018.07.005. Epub 2018 Jul 7. Review.

PMID:
30213396
26.

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I.

Am J Hematol. 2018 Nov;93(11):1318-1326. doi: 10.1002/ajh.25243. Epub 2018 Oct 20.

PMID:
30094870
27.

Personal microbiological consultations improve the therapeutic management of Staphylococcus aureus bacteremia.

Kampmeier S, Correa-Martinez CL, Peters G, Mellmann A, Kahl BC.

J Infect. 2018 Oct;77(4):349-356. doi: 10.1016/j.jinf.2018.07.011. Epub 2018 Jul 29. No abstract available.

PMID:
30067944
28.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL.

Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.

29.

Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.

Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B.

Am J Hematol. 2018 Nov;93(11):1311-1317. doi: 10.1002/ajh.25228. Epub 2018 Aug 31.

30.

[CF Lung Disease - a German S3 Guideline: Module 2: Diagnostics and Treatment in Chronic Infection with Pseudomonas aeruginosa].

Schwarz C, Schulte-Hubbert B, Bend J, Abele-Horn M, Baumann I, Bremer W, Brunsmann F, Dieninghoff D, Eickmeier O, Ellemunter H, Fischer R, Grosse-Onnebrink J, Hammermann J, Hebestreit H, Hogardt M, Hügel C, Hug M, Illing S, Jung A, Kahl B, Koitschev A, Mahlberg R, Mainz JG, Mattner F, Mehl A, Möller A, Muche-Borowski C, Nüßlein T, Puderbach M, Renner S, Rietschel E, Ringshausen FC, Schmidt S, Sedlacek L, Sitter H, Smaczny C, Tümmler B, Vonberg R, Wielpütz MO, Wilkens H, Wollschläger B, Zerlik J, Düesberg U, van Koningsbruggen-Rietschel S.

Pneumologie. 2018 May;72(5):347-392. doi: 10.1055/s-0044-100191. Epub 2018 May 14. German.

PMID:
29758578
31.

Prevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany.

Seufert R, Sedlacek L, Kahl B, Hogardt M, Hamprecht A, Haase G, Gunzer F, Haas A, Grauling-Halama S, MacKenzie CR, Essig A, Stehling F, Sutharsan S, Dittmer S, Killengray D, Schmidt D, Eskandarian N, Steinmann E, Buer J, Hagen F, Meis JF, Rath PM, Steinmann J.

J Antimicrob Chemother. 2018 Aug 1;73(8):2047-2053. doi: 10.1093/jac/dky147.

PMID:
29684150
32.

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.

King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR.

Blood Cancer J. 2018 Feb 28;8(3):27. doi: 10.1038/s41408-018-0064-9.

33.

Targeting BCL-2 in Hematologic Malignancies.

Khan N, Kahl B.

Target Oncol. 2018 Jun;13(3):257-267. doi: 10.1007/s11523-018-0560-7. Review.

PMID:
29520705
34.

Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study.

Schwerdt M, Neumann C, Schwartbeck B, Kampmeier S, Herzog S, Görlich D, Dübbers A, Große-Onnebrink J, Kessler C, Küster P, Schültingkemper H, Treffon J, Peters G, Kahl BC.

Int J Med Microbiol. 2018 Aug;308(6):631-639. doi: 10.1016/j.ijmm.2018.02.003. Epub 2018 Feb 24.

PMID:
29501453
35.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A.

Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.

36.

Are Expectations the Missing Link between Life History Strategies and Psychopathology?

Kavanagh PS, Kahl BL.

Front Psychol. 2018 Feb 6;9:89. doi: 10.3389/fpsyg.2018.00089. eCollection 2018.

37.

Indolent lymphomas.

Kahl B.

Best Pract Res Clin Haematol. 2018 Mar;31(1):1. doi: 10.1016/j.beha.2018.01.001. Epub 2018 Feb 1. No abstract available.

PMID:
29452659
38.

Adaptation of Staphylococcus aureus to Airway Environments in Patients With Cystic Fibrosis by Upregulation of Superoxide Dismutase M and Iron-Scavenging Proteins.

Treffon J, Block D, Moche M, Reiss S, Fuchs S, Engelmann S, Becher D, Langhanki L, Mellmann A, Peters G, Kahl BC.

J Infect Dis. 2018 Apr 11;217(9):1453-1461. doi: 10.1093/infdis/jiy012.

PMID:
29325044
39.

Follicular lymphoma: are we ready for a risk-adapted approach?

Kahl BS.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):358-364. doi: 10.1182/asheducation-2017.1.358. Review.

40.

Staphylococcus aureus and Pseudomonas aeruginosa Respiratory Tract Coinfection-What Can We Learn From Animal Models?

Kahl BC.

J Infect Dis. 2018 Mar 5;217(6):854-856. doi: 10.1093/infdis/jix624. No abstract available.

PMID:
29216374
41.

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S.

Blood. 2018 Feb 22;131(8):877-887. doi: 10.1182/blood-2017-05-786566. Epub 2017 Nov 30.

42.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e61-e67. doi: 10.1016/j.clml.2017.10.006. Epub 2017 Nov 4.

43.

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.

Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L.

Blood Cancer J. 2017 Nov 23;7(12):632. doi: 10.1038/s41408-017-0005-z. No abstract available.

44.

Male kidney allograft recipients at risk for urinary tract infection?

Thölking G, Schuette-Nuetgen K, Vogl T, Dobrindt U, Kahl BC, Brand M, Pavenstädt H, Suwelack B, Koch R, Reuter S.

PLoS One. 2017 Nov 16;12(11):e0188262. doi: 10.1371/journal.pone.0188262. eCollection 2017.

45.

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Nov;15(11):1414-1427. doi: 10.6004/jnccn.2017.0165.

PMID:
29118233
46.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM.

Cancer. 2018 Jan 1;124(1):136-144. doi: 10.1002/cncr.30979. Epub 2017 Sep 13.

47.

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Cavazos N, Liu B, Yang S, Clow F, Goldberg JD, Beaupre D, Vermeulen J, Wildgust M, Wang M.

Br J Haematol. 2017 Nov;179(3):430-438. doi: 10.1111/bjh.14870. Epub 2017 Aug 18.

48.

Current and emerging treatment options for mantle cell lymphoma.

Fakhri B, Kahl B.

Ther Adv Hematol. 2017 Aug;8(8):223-234. doi: 10.1177/2040620717719616. Epub 2017 Jul 7. Review.

49.

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM.

Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017.

50.

Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.

Cohen JB, Zain JM, Kahl BS.

Am Soc Clin Oncol Educ Book. 2017;37:512-525. doi: 10.14694/EDBK_175448. Review.

PMID:
28561694

Supplemental Content

Support Center